Evaluation of the effect of ivermectin in intubated patients 19

Phase 3

Recruiting

• Conditions: COVID-19, virus not identified.; COVID-19, virus not identified; U07.2

• Registration Number: IRCT20190417043295N2
• Lead Sponsor: Ahvaz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 1 November 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Covid PCR test 19 positive
Intubated patient
No increase in liver enzymes

Exclusion Criteria

History of drug allergy
Pregnant Women
Withdrawal of the patient's family from continuing to participate in the study

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Mortality rate. Timepoint: 30 days range, Daily from the time the patient enters the study. Method of measurement: Vital sign check in 30 days range.

Secondary Outcome Measures

Name	Time	Method
Intubation period. Timepoint: in 30 day range, Daily from the time the patient enters the study. Method of measurement: Visual Observation.;Lung Compliance. Timepoint: Daily from the time the patient enters the study. Method of measurement: Calculated based on ventilator data.